Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;33(10):1953-1954.
doi: 10.1681/ASN.2022050609. Epub 2022 Aug 10.

Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!

Dorin-Bogdan Borza  1 , Pallavi Manral
Affiliations
Comment

Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!

Dorin-Bogdan Borza et al. J Am Soc Nephrol. 2022 Oct.
No abstract available

Keywords: anti-GBM disease; anti-hinge antibodies; endopeptidase therapy; imlifidase.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed effects of anti-hinge antibodies in patients with anti-GBM disease who are treated with IdeS. (A) Anti-GBM IgG1 autoantibodies (blue) bound to the GBM (maroon) mediate inflammation (red starburst) via their Fc region. (B) Treatment with IdeS cleaves GBM-bound IgG1, removing the Fc fragments which carry out effector functions. (C) Anti-hinge antibodies (red) recognize neoepitopes generated when IgG1 is cleaved by IdeS, restoring the effector functions of the proteolytically inactivated anti-GBM F(ab′)2 fragments.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, et al. : Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol 33: 829–838, 2022 - PMC - PubMed
    1. Yang R, Otten MA, Hellmark T, Collin M, Björck L, Zhao MH, et al. : Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant 25: 2479–2486, 2010 - PubMed
    1. Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, et al. : Anti-hinge antibodies recognize igg subclass- and protease-restricted neoepitopes. J Immunol 198: 82–93, 2017 - PubMed
    1. Fumia S, Goede JS, Fischler M, Luginbühl A, Frick S, Fodor P, et al. : Human F(ab’)2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol Immunol 45: 2951–2961, 2008 - PubMed
    1. Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, et al. : A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs 6: 1265–1273, 2014 - PMC - PubMed

Publication types

LinkOut - more resources